CASE {#s1}
====

A 22-year-old man was referred for infectious diseases consultation in January 2017. He had a past medical history of a bicuspid aortic valve with mechanical aortic valve replacement at our hospital in June 2015. He reported a 1-year history of intermittent drenching night sweats, occurring 1--2 days per week. He denied other constitutional symptoms, fever, weight loss, chest pain, or dyspnea. He reported a small pustule on the superior aspect of his sternotomy incision that had resolved with a seven-day course of cephalexin 2 months prior to presentation. He was taking warfarin and aspirin. On examination, he looked well with normal vital signs. Cardiorespiratory examination was unremarkable. There was no evidence of lymphadenopathy or organomegaly. His sternotomy incision was well healed with no step deformity or instability. Preliminary investigations showed normal complete blood count parameters, electrolytes, creatinine, liver enzymes, and C-reactive protein. Chest x-ray was normal. Transthoracic echocardiogram performed in January 2017 at another center was reported as normal. Investigation for infectious causes including blood cultures, HIV serology, viral hepatitis serology, and syphilis serology were negative. A single mycobacterial blood culture was collected and ultimately reported negative after 7 weeks of incubation.

In March 2017, the patient presented to the hospital with a 1-week history of chest pain. He was hemodynamically stable on presentation. Laboratory investigations showed normal complete blood count parameters and a slightly elevated troponin I of 0.07 ug/L (normal being ≤0.02 ug/L). Electrocardiogram showed normal sinus rhythm. Computed tomography of his chest revealed a dissection of his ascending aorta with a large aortic pseudoaneurysm ([Figure 1](#F1){ref-type="fig"}). He underwent urgent repair of his aortic dissection with placement of a prosthetic graft. His existing mechanical aortic valve was not replaced as transthoracic and transesophageal echocardiograms showed no evidence of endocarditis or paravalvular abscess. Intraoperative specimens were sent for bacterial and mycobacterial culture. An intraoperative specimen was also submitted for pathologic examination; however, only thrombus was identified. He was discharged with infectious diseases follow-up pending intraoperative tissue culture results.

![Computed tomography of patient with *Mycobacterium chimaera* infection presenting with aortic dissection with large aortic pseudoaneurysm. \*Red arrow indicates false lumen (ie, pseudoaneurysm) of the ascending aorta.](ofy01801){#F1}

After 21 days of incubation, intraoperative tissue cultures identified a *Mycobacterium* species ultimately identified as *Mycobacterium chimaera*. The isolate was sent to the National Microbiology Laboratory (NML; Winnipeg, MB, Canada) for confirmation of identification and whole-genome sequencing. Whole-genome sequencing showed a high degree of relatedness to *M. chimaera* isolates from LivaNova 3T Heater Cooler Units (HCU) used at the University of Alberta Hospital in Edmonton and to publicly available genomes of isolates associated with the HCU outbreak from the United States and Europe ([Supplementary Figure 1](#sup2){ref-type="supplementary-material"}). The draft sequence covered \>99% of the genome with a depth of coverage \~50× as compared with the reference sequence ZUERICH-1 (Accession No. CP015267). The HCU used at the time of his original aortic valve replacement in 2015 could not be confirmed. The total time from cardiovascular surgery to initial clinical presentation was 18.8 months, and the time from clinical presentation to microbial diagnosis was 82 days. Susceptibility results performed by microbroth dilution are summarized in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

The patient was treated with a combination of azithromycin, rifabutin, ethambutol, and amikacin. When susceptibility results were reported, ethambutol was changed to moxifloxacin. The patient was referred for ophthalmologic assessment and was found to have no ocular abnormalities. Therapeutic drug monitoring performed at the Infectious Disease Pharmacokinetics Laboratory (Gainesville, FL) confirmed adequate antimicrobial peak concentrations of rifabutin, azithromycin, and moxifloxacin. Amikacin was discontinued after 11 weeks of therapy, when subclinical sensorineural hearing loss was noted on screening audiometry. Ethambutol was thus recommenced. Details of his treatment course are outlined in [Supplementary Figure 2](#sup3){ref-type="supplementary-material"}. Follow-up ophthalmological examination performed after 12 weeks of therapy was normal. At the time of manuscript submission, the patient is doing well after 21 weeks of combination therapy.

In November 2016, the infection control department conducted a retrospective review of all nontuberculous mycobacteria isolated from patients who underwent open chest cardiovascular surgery in Alberta after January 1, 2011. Of 11 500 patients potentially exposed, we identified no other cases of *M. chimaera* infection. As of the date of manuscript acceptance (January 2018), two additional cases of M. chimaera infection have been identified in patients who have undergone cardiovascular surgery at our institution.

DISCUSSION {#s2}
==========

In 2013, Achermann and colleagues reported 2 cases of *M. chimaera* infection that were related by random amplification of polymorphic DNA--polymerase chain reaction \[[@CIT0001]\]. Preliminary investigations did not identify a nosocomial link. The follow-up outbreak investigation identified what has now been recognized as a global outbreak of *M. chimaera* infections associated with contaminated LivaNova 3T HCUs used in cardiothoracic surgery \[[@CIT0002]\]. Subsequent investigations have demonstrated that *M. chimaera* isolated from HCUs can be aerosolized and spread to the environment via the exhaust fan, resulting in airborne transmission to the patient \[[@CIT0002], [@CIT0003]\]. Whole-genome sequencing has demonstrated that globally distributed clinical cases are genetically similar, suggesting a common-source outbreak involving the manufacturing of LivaNova 3T HCUs \[[@CIT0004]\]. Hospital-level contamination of other brands of HCUs (eg, Maquet) with *M. chimaera* has been described, though these do not appear to be related to the epidemic strain \[[@CIT0004]\].

The earliest described sentinel surgery with subsequent *M. chimaera* infection was 2006 \[[@CIT0005]\]. No cases have yet been associated with LivaNova HCUs manufactured after modifications were made to the manufacturing and maintenance processes in September 2014. LivaNova holds approximately 70% of the global market share, and the majority of HCUs in clinical use were manufactured between 2006 and November 2014. Cardiovascular surgery cannot be performed without HCUs, and existing HCUs cannot be removed from active use without unacceptable disruption in the delivery of cardiovascular surgical services. Infection prevention and control and risk mitigation strategies for *M. chimaera* have been reviewed in detail elsewhere \[[@CIT0005]\]. The precise risk of *M. chimaera* infection after cardiovascular surgery is unknown. A UK national study demonstrated increasing risk of *M. chimaera* infection after cardiovascular surgery over time peaking at 1 in 2000 in 2014 \[[@CIT0003]\]. The Centers for Disease Control and Prevention has estimated the risk to be 1 in 100 to 1 in 1000 infections per surgery in sites that have already had a case \[[@CIT0008]\].

Patients with *M. chimaera* infections most often present with nonspecific symptoms such as fatigue, fever, night sweats, and weight loss \[[@CIT0005], [@CIT0009]\]. Local complications such as sternal osteomyelitis and left ventricular assist device driver site infections have also been described \[[@CIT0005]\]. *M. chimaera* infection presenting with aortic dissection has not been previously described. In cases of *M chimaera* infection, physical examination may show lymphadenopathy, organomegaly, or other signs of disseminated infection. Ophthalmologic examination may show choroidal lesions or uveitis in patients with disseminated disease \[[@CIT0010]\]. Patients with disseminated disease may have laboratory abnormalities such as elevated inflammatory markers (eg, C-reactive protein), cytopenias, and elevated liver enzymes \[[@CIT0007]\]. Which patients should be investigated and which diagnostic investigations should be carried out on suspect patients is not clear \[[@CIT0007]\]. In our case, a single mycobacterial blood culture collected prior to surgery was negative. Even in patients with disseminated infection, mycobacterial blood cultures may be negative \[[@CIT0009]\]. Histopathology of biopsy specimens characteristically shows noncaseating granulomatous inflammation that is rarely acid-fast bacilli stain--positive. A number of reported cases have been misdiagnosed as sarcoidosis or other inflammatory conditions and received immunosuppression prior to the diagnosis of *M. chimaera* infection \[[@CIT0005], [@CIT0009]\]. The median time from cardiovascular surgery to presentation is 17 months, though the longest lag time described is 6 years \[[@CIT0005], [@CIT0007]\]. Clearly, pending further research, clinicians should consider broadly investigating patients with previous cardiac surgery presenting with a wide range of symptoms within the at-risk time frame to avoid missing patients with *M. chimaera* infection.

Optimal treatment of *M. chimaera* infections has not been established. *Mycobacterium chimaera* is genetically related to *Mycobacterium avium* complex \[[@CIT0011]\], and therefore, treatment of *M. chimaera* infection might be expected to be similar to treatment of *M. avium* complex infection. The American Thoracic Society/Infectious Diseases Society of America guidelines for disseminated *M. avium* complex infection recommend a macrolide (clarithromycin or azithromycin) and ethambutol with or without rifabutin \[[@CIT0012]\]. Susceptibility testing, other than for clarithromycin, is not recommended for treatment-naïve patients as there is a lack of correlation between in vitro susceptibility and clinical outcomes. However, it is unknown whether this is true for *M. chimaera*. Susceptibility results are presented here as it is expected that results will be similar for all strains in this clonal outbreak, barring antibiotic exposure and subsequent development of resistance. For *M. chimaera* infections, the combination of a rifamycin (rifabutin or rifampin), ethambutol, and a macrolide is the most commonly described regimen in the literature \[[@CIT0005], [@CIT0009]\]. However, it should be noted that the combination of clarithromycin and rifampin may result in subtherapeutic levels of clarithromycin \[[@CIT0012]\]. A combination of antimicrobial therapy and removal of prosthetic material should be considered when feasible. There are no data on reinfection rates for newly placed prosthetic devices. Patients failing initial therapy or those patients in whom surgical source control cannot be achieved may benefit from the addition of moxifloxacin and/or intravenous amikacin \[[@CIT0009]\]. Optimal treatment duration in patients with disseminated disease or those with retained prosthetic devices has not been established. The crude mortality rate of reported cases is approximately 50% \[[@CIT0007]\]. Cure has been achieved for patients with limited disease (eg, sternal osteomyelitis) treated with surgical debridement and prolonged antimicrobials \[[@CIT0005]\].

CONCLUSIONS {#s3}
===========

We report the first case of *M. chimaera* infection associated with the global HCU outbreak in Western Canada. To our knowledge, this is also the first description of *M. chimaera* infection presenting with aortic dissection. Our case also highlights the challenge in making the diagnosis, especially when patients do not have disseminated disease or clinically apparent localized infection such as sternal osteomyelitis. *M. chimaera* infections will remain difficult to diagnose given the long incubation period and typically nonspecific presentation. Vigilance is necessary to identify patients potentially at risk, and we would advise clinicians to consider *M. chimaera* infection in those patients with previous aortic surgery presenting with aortic dissection or pseudoaneurysm.
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Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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